653. Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in MM ? Join us 9:30 AM for some thought-provoking abstracts ASH Joushua Gustine Xinhe Shan Rahul Banerjee, MD, FACP and may more #mmsm MCW Cancer Center #ASH24

#ASH24 looking forward to this excellent session about how to make myeloma #MMsm response assessments work better! Meera Mohan Shashank Cingam as the awesome moderators!

#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm Thanos Dimopoulos

Say it with me: 'Arlo-cel' - GPRC5D -directed CAR T presented by Susan Bal We see a very high ORR (91%) at the 150 x 10^6 dose. mPFS of 18 months Skin, nail, taste changes seem less, and less prolonged. There is a known neurotoxicity (12% all grades, 7% grade 3-4)

Honored to have delivered our abstract as an oral presentation at ASH '24. Teclistamab can be given safely and effectively in the community bringing the drug more directly to the patients who need it! HealthTree Foundation Aimaz Afrough UTSW Simmons Cancer Center Larry Anderson,MD,PhD,FACP Flatiron Health

Audrey is immensely supportive. She is a constant and eager pool of information and institutional knowledge. She steps in immediately to cover her teammates' patients. She was able to help two new hires with grace and kindness.

An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star Alain Mina ashpublications.org/bloodadvances/…

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia nature.com/articles/s4137…

Dr. Punita Grover University of Minnesota showing ⬆️ chronic #GVHD with #PTCy/siro/MMF vs PTCy/tac/MMF in a sequential phase II well matched myeloablaive study setting ⚡️#Tandem25

#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. Simultaneous JCO pub, highlighted NY Times ascopubs.org/doi/10.1200/JC… nytimes.com/2025/06/03/hea…

“Nonclassical” myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. ow.ly/5knJ50W1ftQ #myeloidneoplasia #transplantation

Dr.Dalia Hammoud presents on updates prostate cancer #BestofASCO2025 #Shreveport Binaytara LSU Health Shreveport

Dr.Brian Halbert Ochsner Health presenting updates in Baldder Cancer at #BestofASCO2025 Binaytara #Shreveport

Dr.Marc Matrana Ochsner Health kicks-off the Best of ASCO 2025 in Shreveport #BestofASCO2025 #Shreveport Binaytara

Dr. Yu Cao UTSW Simmons Cancer Center presenting updates on Head and neck cancer #BestofASCO2025 Binaytara #Shreveport

Dr.Sindhu Devarashetty LSU Health Shreveport presenting updates on Ovarian Cancer #BestofASCO2025 Binaytara #Shreveport

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia - Kidney International kidney-international.org/article/S0085-…